Study of Galantamine for the treatment of Alzheimer's disease based on real world

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400094516

Enrollment

Unknown

Registered

2024-12-24

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease Cognitive dysfunction

Interventions

Galantamine group:NA

non-Galantamine group:NA

Eligibility

Sex/Gender

All

Age

50 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Refer to the 2020 edition of the "China Alzheimer's Dementia Diagnosis and Treatment Guide" for patients diagnosed with Alzheimer's disease; 2.The patient showed obvious clinical symptoms and progressive memory function decline for more than half a year;

Exclusion criteria

Exclusion criteria: 1.People without Alzheimer's disease;

Design outcomes

Primary

Measure	Time frame
Activity of Daily Living Scale,ADL);Mini Mental State Examination (MMSE);Neuropsychiatric Inventory or Neuropsychiatric Inventory-Questionnaire;	—

Countries

China

Contacts

Public ContactYu Zhe

Hangzhou First People's Hospital

yuzhe77@126.com+86 571 56234203

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026